{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T03:19:47Z","timestamp":1783826387178,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":2668,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Merck","award":["GCIG006-1a"],"award-info":[{"award-number":["GCIG006-1a"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1093\/annonc\/mdr583","type":"journal-article","created":{"date-parts":[[2012,1,31]],"date-time":"2012-01-31T07:04:03Z","timestamp":1327993443000},"page":"2020-2027","source":"Crossref","is-referenced-by-count":39,"title":["Health-related quality of life in recurrent platinum-sensitive ovarian cancer\u2014results from the CALYPSO trial"],"prefix":"10.1016","volume":"23","author":[{"given":"M.","family":"Brundage","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gropp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Mefti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Wolfram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Pujade-Lauraine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdr583_bb0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/gyno.2001.6552","article-title":"Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer","volume":"85","author":"Covens","year":"2002","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdr583_bb0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3747\/co.2007.148","article-title":"Optimal chemotherapy treatment for women with recurrent ovarian cancer","volume":"14","author":"Fung-Kee-Fung","year":"2007","journal-title":"Curr Oncol"},{"key":"10.1093\/annonc\/mdr583_bb0020","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr583_bb0025","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr583_bb0030","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdr583_bb0035","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mdi147","article-title":"Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol De Investigacion En Cancer De Ovario) study","volume":"16","author":"Gonzalez-Martin","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdr583_bb0040","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2002.20.5.1232","article-title":"Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens","volume":"20","author":"Cantu","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdr583_bb0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/gyno.2001.6151","article-title":"Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer","volume":"81","author":"Bolis","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdr583_bb0050","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdr583_bb0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0959-8049(00)00369-5","article-title":"Development of a European organization for research and treatment of cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report","volume":"37","author":"Cull","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdr583_bb0060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00451727","article-title":"Psychometric properties and responsiveness of the EORTC quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer","volume":"3","author":"Osoba","year":"1994","journal-title":"Qual Life Res"},{"key":"10.1093\/annonc\/mdr583_bb0065","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejca.2004.10.017","article-title":"Quality of Life Committee of the NCIC CTG analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the National Cancer Institute of Canada Clinical Trials Group","volume":"41","author":"Osoba","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdr583_bb0070","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s11136-007-9223-3","article-title":"How can quality of life researchers make their work more useful to health workers and their patients?","volume":"16","author":"Guyatt","year":"2007","journal-title":"Qual Life Res"},{"key":"10.1093\/annonc\/mdr583_bb0075","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s00520-006-0085-y","article-title":"Clinical Significance Consensus Meeting Group. The clinical significance of quality of life assessments in oncology: a summary for clinicians","volume":"14","author":"Sloan","year":"2006","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdr583_bb0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11136-008-9430-6","article-title":"The applications of PROs in clinical practice: what are they, do they work, and why?","volume":"18","author":"Greenhalgh","year":"2009","journal-title":"Qual Life Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419381001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419381001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/23\/8\/2020\/315063\/mdr583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T09:18:00Z","timestamp":1624439880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419381001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0923753419381001"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdr583","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}